Company Overview

Entera Bio Ltd. is a clinical-stage biotechnology company focused on the oral delivery of biologic therapies and large molecules that are traditionally administered by injection. The company operates within the biotechnology and pharmaceutical industries, with a strategic emphasis on developing oral formulations for peptides, proteins, and other biologics using its proprietary delivery platform technology. Entera Bio’s primary revenue and value drivers are tied to the advancement, licensing potential, and commercialization prospects of its clinical pipeline, particularly oral formulations targeting bone health and metabolic diseases.

The company’s core technology platform, known as N-Tab™, is designed to enable the oral absorption of biologic compounds by improving gastrointestinal delivery and bioavailability. Entera Bio has concentrated development efforts on oral peptide therapeutics, including programs related to parathyroid hormone and GLP-1 receptor agonists. Founded in Israel and later listed on the Nasdaq Capital Market under the ticker ENTX, the company evolved from a platform-focused drug delivery developer into a clinical-stage therapeutics company with strategic collaborations in endocrinology and metabolic disease markets.

Business Operations

Entera Bio conducts operations primarily through its research, clinical development, and intellectual property management activities. The company’s business model centers on advancing proprietary oral biologic candidates through clinical development while also seeking licensing agreements, development collaborations, and potential commercialization partnerships. Its principal operating assets include the N-Tab™ oral delivery platform and associated formulation technologies designed for peptide and protein therapeutics.

The company’s leading development programs have included oral formulations of parathyroid hormone candidates for osteoporosis and hypoparathyroidism, as well as oral GLP-1-based therapeutic programs for obesity and metabolic disorders. Entera Bio has engaged in strategic collaborations, including a development collaboration with OPKO Health, Inc. involving oral formulations of parathyroid hormone analogs. Operations are primarily managed from Israel, while the company also maintains access to U.S. capital markets and engages with international clinical and pharmaceutical partners.

Strategic Position & Investments

Entera Bio’s strategic direction is focused on establishing oral biologic delivery as a differentiated alternative to injectable therapies. The company has prioritized indications where chronic injectable treatment creates adherence challenges, particularly in endocrinology, osteoporosis, obesity, and metabolic disease management. Its development strategy emphasizes leveraging the N-Tab™ platform across multiple therapeutic categories while pursuing partnerships that may reduce development costs and expand commercialization opportunities.

The company has invested substantially in clinical-stage development programs and intellectual property related to oral peptide delivery technologies. Entera Bio has also expanded efforts in obesity and metabolic disease therapeutics through preclinical and clinical work involving oral GLP-1 receptor agonist formulations. Its collaboration activities and pipeline positioning reflect broader pharmaceutical industry interest in non-invasive biologic delivery technologies, especially within rapidly growing obesity and diabetes treatment markets. Public filings and corporate disclosures indicate that the company continues to evaluate strategic partnerships and pipeline expansion opportunities aligned with its delivery platform capabilities.

Geographic Footprint

Entera Bio is headquartered in Jerusalem, Israel, and maintains a public market presence in the United States through its Nasdaq listing. The company’s operational footprint is concentrated primarily in Israel for research and development activities, while its financing, investor engagement, and potential commercial partnerships extend into the North American biotechnology and pharmaceutical markets.

The company’s clinical development activities and strategic collaborations have international dimensions, including engagement with U.S.-based partners and service providers involved in clinical trials, manufacturing, and regulatory support. Although Entera Bio does not currently operate large-scale commercial infrastructure globally, its intellectual property strategy and therapeutic targets are intended for major pharmaceutical markets including North America, Europe, and other regions with significant demand for metabolic and endocrine therapies.

Leadership & Governance

Entera Bio’s leadership team combines biotechnology, pharmaceutical development, finance, and commercialization experience. The company’s governance structure follows standard Nasdaq-listed biotechnology company practices, with oversight provided by its board of directors and executive management team. Public company disclosures indicate that leadership strategy has focused on advancing oral biologics technology, securing strategic partnerships, and prioritizing clinical-stage assets with significant commercial market potential.

Key executives include:

• Miranda Toledano – Chief Executive Officer
• Amit Shaltiel – Chairman of the Board
• Mark Oppenheimer – Chief Financial Officer
• Adiv Baruch – Chief Business Officer

Management communications and public filings emphasize a strategic vision centered on transforming injectable biologic therapies into orally administered treatments through proprietary drug delivery technologies, with particular focus on scalability, patient convenience, and differentiation within competitive therapeutic markets.